High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Measurable residual disease (MRD) is highly prognostic for relapse and overall survival (OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent “MRD negativity” by standard assays still relapse. We evaluated the clinical impact of a highly sensitive next-generation sequencin...

Descripción completa

Detalles Bibliográficos
Autores principales: Short, Nicholas J., Kantarjian, Hagop, Ravandi, Farhad, Konopleva, Marina, Jain, Nitin, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Macaron, Walid, Kadia, Tapan M., Wang, Sa, Jorgensen, Jeffrey L., Khoury, Joseph D., Yilmaz, Musa, Kebriaei, Partow, Takahashi, Koichi, Garcia-Manero, Guillermo, Daver, Naval, Post, Sean M., Huang, Xuelin, Kornblau, Steven M., Pelletier, Sara, Flores, Wilmer, Matthews, Jairo, Garris, Rebecca, Jabbour, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278301/
https://www.ncbi.nlm.nih.gov/pubmed/35533262
http://dx.doi.org/10.1182/bloodadvances.2022007378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278301/
https://www.ncbi.nlm.nih.gov/pubmed/35533262
http://dx.doi.org/10.1182/bloodadvances.2022007378

Ejemplares similares